Praetego, founded in Durham, North Carolina, is a pharmaceutical company dedicated to addressing serious complications associated with diabetes and age-related neurodegeneration. The company's core mission is to protect patients by developing novel small molecule candidates, known as Amadorins, which target common pathways in disease progression. Praetego's vision is to limit conditions such as Alzheimer's disease and other aging-related diseases through their innovative therapeutic approach.
Notable affiliated individuals include experts in pharmaceutical development and neurodegenerative research. Praetego has garnered attention from investors focused on groundbreaking medical advancements. The company has achieved significant milestones in preclinical trials, demonstrating the efficacy of their Amadorins in protecting against disease progression. Praetego's impact lies in its potential to transform the treatment landscape for diabetes complications and neurodegenerative diseases, offering hope for improved patient outcomes.
